Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -325.10M | -304.96M | -297.91M | -289.04M | -277.42M |
| Total Depreciation and Amortization | 1.67M | 1.38M | 1.10M | 910.00K | 765.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.23M | 93.74M | 89.47M | 84.24M | 76.99M |
| Change in Net Operating Assets | -583.00K | -4.45M | 23.91M | 29.19M | 38.10M |
| Cash from Operations | -222.80M | -214.29M | -183.43M | -174.69M | -161.56M |
| Capital Expenditure | -7.39M | -11.44M | -11.35M | -10.79M | -10.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.14M | -149.61M | -98.07M | -132.63M | -205.40M |
| Cash from Investing | 34.75M | -161.05M | -109.42M | -143.42M | -215.60M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 299.44M | 413.00K | 340.83M | 340.96M | 342.04M |
| Repurchase of Common Stock | -2.80M | -2.55M | -2.50M | -2.37M | -1.34M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 296.64M | -2.13M | 338.34M | 338.59M | 340.70M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.60M | -377.48M | 45.49M | 20.48M | -36.46M |